ERBB2 and breast cancer: Taxane/carboplatin/trastuzumab/pertuzumab (TCbHP) and taxane/trastuzumab/pertuzumab (THP) are two class I recommendations in the 2021 version of Chinese Society of Clinical Oncology breast cancer guideline, while other regimens based on anti-HER2 monoclonal antibody and taxane (such as anthracycline/cyclophosphamide followed by taxane/trastuzumab/pertuzumab [AC-THP]) are class II recommendations (3, 4).